13.45
1.56 (13.12%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Invizyne Technologies Inc. | - | - |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | 2.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 0.0 |
Average | 0.63 |
Invizyne Technologies Inc is redefining biomanufacturing by leveraging cell-free multi-step enzyme-based systems to efficiently transform natural or renewable resources into highly sought-after chemicals. It believes that its biomanufacturing platform, known as SimplePath, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. its objective with SimplePath is to enable the efficient production of a diverse range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform consists of a series of modular cascading enzyme-based biomanufacturing systems that leverage natural processes to perform complex chemical conversions. |
|
Sector | Healthcare |
Industry | Biotechnology |
% Held by Insiders | 76.34% |
% Held by Institutions | 0.62% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |